Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug.

L-dopa-α-lipoic acid (LD-LA) is a new multifunctional prodrug for the treatment of Parkinson's disease. In human plasma, LD-LA catechol esters and amide bonds are chemically and enzymatically cleaved, respectively, resulting in a half-life time of about fifty minutes. In the present work, the unstable LD-LA was entrapped into biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres designed as depot systems to protect this prodrug against degradation and to obtain a sustained release of the intact compound. The microspheres were prepared by an oil-in-water emulsion/solvent evaporation technique and the effect of formulation and processing parameters (polymer concentration in the organic solvent, volumes ratio of the phases, rate of the organic solvent evaporation) on microspheres characteristics (size, loading, morphology, release) was investigated. Also emphasis was given on the stability of the drug before and after release as well as on the underlying mass transport mechanisms controlling LD-LA release. Interestingly, when encapsulated in appropriate conditions into PLGA microspheres, the labile prodrug was stabilized and released via Fickian diffusion up to more than one week.

[1]  Motohiro Uo,et al.  Microparticle formation and its mechanism in single and double emulsion solvent evaporation. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[2]  J. Siepmann,et al.  Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Kinam Park,et al.  Issues in long-term protein delivery using biodegradable microparticles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[4]  K. Zhu,et al.  Preparation and in vitro release behaviour of 5-fluorouracil-loaded microspheres based on poly (L-lactide) and its carbonate copolymers. , 2003, Journal of microencapsulation.

[5]  R. Herrero-Vanrell,et al.  Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. , 2004, International journal of pharmaceutics.

[6]  R. Duvoisin,et al.  History of parkinsonism. , 1987, Pharmacology & therapeutics.

[7]  C. Demerlis,et al.  Review of the oral toxicity of polyvinyl alcohol (PVA). , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  C. van Nostrum,et al.  Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid). , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. Kressler,et al.  Tracking the urinary excretion of high molar mass poly(vinyl alcohol). , 2007, Journal of biomedical materials research. Part B, Applied biomaterials.

[10]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[11]  R. A. Jain,et al.  The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.

[12]  S. Fahn,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[13]  R. Jalil,et al.  Microencapsulation using poly (L-lactic acid) II: Preparative variables affecting microcapsule properties. , 1990, Journal of microencapsulation.

[14]  R. Mehta,et al.  Biodegradable Polyesters for Drug and Polypeptide Delivery , 1993 .

[15]  G. Giorgioni,et al.  Dimeric L-dopa derivatives as potential prodrugs. , 2001, Bioorganic & medicinal chemistry letters.

[16]  S. Sahoo,et al.  Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[17]  L. Perioli,et al.  Ketoprofen poly(lactide-co-glycolide) physical interaction , 2007, AAPS PharmSciTech.

[18]  F. Blandini,et al.  Protective and symptomatic strategies for therapy of Parkinson's disease. , 1999, Drugs of Today.

[19]  A. Bindoli,et al.  Biochemical and toxicological properties of the oxidation products of catecholamines. , 1992, Free radical biology & medicine.

[20]  Aliasger K Salem,et al.  Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. , 2008, Journal of pharmaceutical sciences.

[21]  T. Aminabhavi,et al.  Ethyl acetate as a dispersing solvent in the production of poly(DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type , 2002, Journal of microencapsulation.

[22]  R. Gurny,et al.  In Vitro Extended-Release Properties of Drug-Loaded Poly(DL-Lactic Acid) Nanoparticles Produced by a Salting-Out Procedure , 1993, Pharmaceutical Research.

[23]  J. Benoit,et al.  Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. , 2003, Biomaterials.

[24]  Chi-Hwa Wang,et al.  Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. , 2006, Advanced drug delivery reviews.

[25]  Steven P Schwendeman,et al.  Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.

[26]  Y. Zhang,et al.  A new class of inhibitors of peptide sorption and acylation in PLGA. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[27]  A. Hisaka,et al.  Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. , 1990, Journal of pharmaceutical sciences.

[28]  Wenlei Jiang,et al.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.

[29]  W. Gibb,et al.  Neuropathology of Parkinson's disease and related syndromes. , 1992, Neurologic clinics.

[30]  Samuel M. Goldman,et al.  EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.

[31]  Daniel W Pack,et al.  Microspheres for controlled release drug delivery , 2004, Expert opinion on biological therapy.

[32]  M. Shive,et al.  Biodegradation and biocompatibility of PLA and PLGA microspheres , 1997 .

[33]  J. Benoit,et al.  Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. , 2006, International journal of pharmaceutics.

[34]  L. Perioli,et al.  Physicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. , 2008, Journal of pharmaceutical sciences.

[35]  J. Andersen Iron dysregulation and Parkinson's disease. , 2005, Journal of Alzheimer's disease : JAD.

[36]  K. Johnston,et al.  Encapsulation of protein nanoparticles into uniform-sized microspheres formed in a spinning oil film , 2005, AAPS PharmSciTech.

[37]  L. Packer,et al.  Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid , 1997 .

[38]  J. Siepmann,et al.  PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  A H V Schapira,et al.  Levodopa in the treatment of Parkinson’s disease , 2009, European journal of neurology.

[40]  M. Widlansky,et al.  Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. , 2004, Current medicinal chemistry.

[41]  Xin Sun,et al.  NMR spectroscopic evaluation of the internal environment of PLGA microspheres. , 2008, Molecular pharmaceutics.

[42]  E. Santucci,et al.  L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties. , 2006, Journal of medicinal chemistry.

[43]  T. Burke,et al.  The Acidic Microclimate in Poly(lactide-co-glycolide) Microspheres Stabilizes Camptothecins , 1999, Pharmaceutical Research.

[44]  P. Riederer,et al.  Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.

[45]  A. Mitra,et al.  Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres. , 2007, International journal of pharmaceutics.